Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

ºñÈ£ÁöŲ ¸²ÇÁÁ¾¿¡ ´ëÇÑ COP-BLAM º¹ÇÕÈ­Çпä¹ýÀÇ Ä¡·áÈ¿°ú COP-BLAM Combination Chemotherapy for the Treatment of Intermediated and High Grade Non-Hodgkin's Lymphoma

´ëÇѾÏÇÐȸÁö 1994³â 26±Ç 5È£ p.806 ~ 814
ÀÌÀ缺, ¼­Àå¼ö, Çö¸í¼ö,
¼Ò¼Ó »ó¼¼Á¤º¸
ÀÌÀ缺 (  ) 
¿µ³²´ëÇб³

¼­Àå¼ö (  ) 
¿µ³²´ëÇб³
Çö¸í¼ö (  ) 
¿µ³²´ëÇб³

Abstract


Between March 1987 and December 1993, 45 patients with intermediate and high grade non-Hodgkin's lymphoma were treated with a COP-BLAM(cyclophosphamide, oncovin, prednisone, procarbazine, bleomycin, adriamycin) combination chemotherapy.
The median age was 49 years(range 16-76). 29 patients were male and 16 patients were female. The common histologic types were diffuse large cell type(68.9%), diffuse small cleaved cell type(13.3%), and diffuse mixed small and large cell
type(11.1%). The
proportion of patients with 'B' symptom, bulky mass, and LDH>550IU/L at diagnosis was 42.4%, 6.7%, 33.3%, respectively.
The rate of complete remission was 71.1%, and overall response rate was 93.3%. 2 year survival rate was 76.8%, but the median survival time was not reached right now(the median follow up time: 17 months). Age, serum LDH level at diagnosis, lower
performance scale, stage, and bulky mass were significantly associated with 2 year survival rate. Overall toxicity was acceptible without any treatment related deaths.

Å°¿öµå

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS